Ken Griffin Bridge Bio Pharma, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 256,900 shares of BBIO stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
256,900
Previous 383,200
32.96%
Holding current value
$12.6 Million
Previous $10.5 Million
15.54%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding BBIO
# of Institutions
392Shares Held
187MCall Options Held
12.7MPut Options Held
2.28M-
Viking Global Investors LP22.1MShares$1.08 Billion2.55% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY19.3MShares$946 Million30.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.5MShares$809 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$611 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.17MShares$352 Million0.14% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $7.28B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...